ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

CHALLENGES IN BRAIN DELIVERY OF ANTI-MIGRAINE DRUGS AND CURRENT INITIATIVES TO IMPROVE THERAPEUTIC OUTCOMES

Harshitha V and Dr. V. Kusum Devi*

Migraine is a common headache which is usually associated with nausea, photophobia and impaired daily activities. However, migraine can be extremely disabling with a considerable impact on the life of an individual in their ability to work. The arrival of triptans in the early 1990s saw a major change in the way migraines were treated, and triptans remain the gold standard in treating an acute attack. In recent times, considerable research has been made in understanding the pathophysiology of migraine. Numerous drug delivery systems have been discovered as therapies for brain disorders which may improve efficacy and reduce the toxic effect of the active compound. The blood brain barrier (BBB) is the most vital elements present in the central nervous system (CNS) which selectively permits the access of preferred molecules from blood to brain. The coming decade will see dramatic improvement in treating and preventing migraine with potential neuro-pharmacological agent and neuro stimulation. This article briefly discusses the different strategies for site specific delivery of anti migrane drugs in treatment of migraine in addition to the pathophysiology and management of migraine. Keywords: Migraine;Triptans; Bbb(Blood Brain Barrier);Neuro-Pharmacological Agent;Specific Delivery.

FULL TEXT